implementation harmonised productinformation (class labelling)
European agreements on modifying product information for
innovative and generic products are made regularly. The MEB strives
to harmonise product information across all medicinal products
(both generic and innovative).
Class labelling is required for various reasons, such as:
Actions after defining texts
The marketing authorisation holder is responsible for
maintaining up-to-date product information. The MEB publishes an
overview of agreed wording for product information per active
substance. The overview contains links to defined product
information. This information is updated on a monthly basis. Newly
added actions can be viewed by selecting the date of decision in
the overview.
There are two types of class labelling:
-
active class labelling (the marketing authorisation holder
is asked in writing to submit a variation)
-
standard class labelling (no explicit request)
In both cases, the relevant marketing authorisation holders must
implement the required changes to the product information by
submitting a
type 1B variation.
CMDh and PhVWP recommendations are published monthly on the CMDh
website (English-language versions of the defined product
information) and since September 2009 also by the PhVWP (concise
evaluation report), in principle one week after the CMDh or PhVWP meeting. An overview of
discussed topics is available on the page:
pharmacovigilance > PhVWP.
Recommendations for SmPC and package leaflets based on Art. 45
and 46 Paediatric Worksharing are also published on the CMDh
website. Dutch translations are published in the overview of agreed
wording.
The texts defined after a CHMP referral are published on
the European Commission's website.
There are currently no European agreements on the publication of
Core Safety Profiles (CSP) defined in the PSUR Worksharing
project. The MEB will publish the CSPs in the
agreed wording until they are published in a ‘central/European
location’.